Business Daily Media

Business Marketing

.

Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation

  • Written by ACN Newswire - Press Releases

image

TOKYO, Jan 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug (AED) Fycompa (perampanel) for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric

Read more //?#

Popular

The Power of the Word “You”

“Handle them carefully, for words have more power than atom bombs.” ~ Pearl Strachan Hurd In a study conducted by Yale University, the word “You” ranked as the most powerful word in the English language. Think about this for a...

80% of Global Top Performing Companies Collaborate with Competitors: TCS Study

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting, and business solutions organisation, published its global study titled ‘Where, How and What Leaders Will Compete With in the Ne...

Half of Aussie start-ups feel ignored by government

More than half of Australian start-up founders feel ignored by governments and policymakers, and a quarter believe Australian regulations have impeded their growth, according to The State of Australian Tech 2020 report compi...